Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, September 16, 2014

AbbVie, Biogen to file for FDA approval of MS drug (daclizumab), next year

September 15, 2014

Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Biogen's injectable Avonex (interferon beta-1a) on some measures among relapse-remitting MS patients.
The companies released the full results at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis last week.
The clinical trial of more than 1,800 patients showed Zinbryta patients had “significantly improved key measures of multiple sclerosis disease activity,” including a 45% reduction in relapses compared to Avonex patients and fewer new brain lesions. Researchers found that 73% of Zinbryta patients were relapse-free after 96 weeks of therapy, compared to Avonex patients, of whom 59% were relapse-free within the same timeframe.
Read More

 Keep CURRENT and up to date, with MS News and Information
Sign-up for emails 



No comments: